Related references
Note: Only part of the references are listed.A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression
Ton Wang et al.
SURGERY (2020)
Inhibitors of HSP90 in melanoma
Aleksandra Mielczarek-Lewandowska et al.
APOPTOSIS (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Old and New Approaches to Target the Hsp90 Chaperone
Jackee Sanchez et al.
CURRENT CANCER DRUG TARGETS (2020)
Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition
Chitra Subramanian et al.
MOLECULAR ONCOLOGY (2020)
Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma
Zeynep Eroglu et al.
CLINICAL CANCER RESEARCH (2018)
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Jaquelyn N. Sanchez et al.
DRUGS (2018)
17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model
Sandeep S. Joshi et al.
PLOS ONE (2018)
Combination therapy in combating cancer
Reza Bayat Mokhtari et al.
ONCOTARGET (2017)
Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells
C. Subramanian et al.
NEOPLASIA (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Jaime Acquaviva et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models
Tomoko Smyth et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Therapeutic Target Hsp90 and Cancer Hallmarks
Yoshihiko Miyata et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Kim H. T. Paraiso et al.
CLINICAL CANCER RESEARCH (2012)
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
Peter Friedl et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
David B. Solit et al.
CLINICAL CANCER RESEARCH (2008)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Share Paper
